Unilife (UNIFF) 8-K Unilife Corporation Announces Financial Results

Fiscal 2014 4th Quarter and

Full Year Earnings Call

September 9, 2014

Exhibit  99.2

Growing Rapidly in Response to Customer Demand

Increasing R&D Investment

•

Revenue was $14.7MM, an increase of $12MM compared to the prior year

•

Deferred revenue increased to $13.3MM

•

Cash receipts was $23.7MM, an increase of $22.5MM compared to the prior year

•

Net

operating

cash

flow

loss

was

narrowed

by

20%

compared

to

the

prior

year

•

Over half of total annual operating expenses was invested in R&D

Fiscal Year 2014 Financial Highlights

Increasing Revenue, Deferred Revenue and Cash Receipts

$-

$5.00

$10.00

$15.00

$20.00

$25.00

FY 2012

FY 2013

FY 2014

Revenue

Deferred Revenue

Cash Receipts from Customers

30%

35%

40%

45%

50%

55%

FY 2012

FY 2013

FY 2014

R&D

SG&A

Execution on Existing Agreements and Programs

A Dozen Active Customer Programs

Accelerating Production Capabilities

•

A dozen active programs as of June 30, 2014

•

Programs span across all six product platforms

•

Additional programs continue to commence

•

A multitude of pharma & biotech customers

Strengthening our High-Caliber Team

•

Brought forward $16MM in cap-ex, R&D and

facilities investments into Q4FY14 to support

customer demand

•

Ramp program for Unifill contracts accelerated

•

Increased production capacity for wearable

injectors earlier than originally anticipated

•

Directing R&D to specific unmet or emerging

market needs of current and future customers

•

Upfront R&D investment a leading indicator of

future agreements and customer relationships

•

Unilife team now more than 210 strong

•

Deep scientific knowledge and expertise

•

80% of staff in product development, customer

programs and manufacturing

Customer-Centric R&D Investment

Results for the 4

th

Quarter and Full Fiscal Year 2014

4Q 2014

4Q 2013

FY 2014

FY 2013

Revenue

$    6.5M

$    0.7M

$     14.7M

$     2.7M

Research & development

$    11.9M

$    6.5M

$   34.1M

$   21.7M

Selling, general & administrative

$    8.0M

$    10.3M

$   27.9M

$   32.4M

Net loss

$  15.3M

$  22.0M

$   57.9M

$   63.2M

Net loss per share –

diluted

$   0.15

$   0.25

$    0.59

$    0.78

Adjusted net loss

$  11.7M

$  9.9M

$   38.8M

$   38.0M

Adjusted

net

loss

per

share

-

diluted

$   0.12

$   0.11

$    0.40

$    0.47

Commercial Expectations

•

•

•

•

•

Upcoming Milestones for Fiscal Year 2015

Financial Expectations

Commenced commercial sale of Unifill syringes

Commercial sale of additional Unifill product

configurations to commence mid-fiscal year

Initial product sales from some other platforms

Receipt of upfront and milestone-based payments

from new and existing customers

Signing of additional long-term supply agreements

from new and existing customers

•

Significant growth in revenue                    

compared to fiscal year 2014

•

Moderation of R&D investment and a

flattening of SG&A

•

Controlled increase in capital expenditure

Questions